Background: Peptic ulcer (PU) and cardiovascular disease (CVD) are significant chronic illnesses, particularly in the elderly. This study investigates the relationship between PU and CVD in older adults and the impact on mortality risk.Methods: This study was conducted utilizing data from a nationwide health survey of the elderly in China. Kaplan–Meier curves and log-rank tests were applied in survival analysis to evaluate mortality differences between the groups. Stratified models were applied to evaluate the effects of factors.Results: This study included 3,636 participants. CVD was significantly associated with an increased PU risk (OR = 1.31, 95%CI 1.03–1.66, p = 0.04), while PU had no significant effect on CVD incidence (OR = 1.08, 95%CI 0.77–1.51, p = 0.64). Mortality risk was significantly higher in the CVD group (HR = 1.22, 95%CI 1.03–1.45, p = 0.02) compared to the non-comorbid group. No significant difference in mortality was observed between the PU-only and combined PU-CVD groups. Stratified analysis identified advanced age (≥75 years) (HR = 1.45, 95%CI 1.06–1.87, p < 0.01) and male gender (HR = 1.29, 95%CI 1.05–1.62, p < 0.01) as significant mortality risk factors among PU patients.Conclusion: PU does not have a significant impact on overall mortality or the prognosis of CVD patients. CVD was a risk factor for PU, but PU did not significantly increase CVD risk. A higher mortality risk was observed in older and male PU patients. These findings suggest the need for gender-sensitive and age-stratified management strategies for PU in high-risk groups.
The etiology of gastric cancer (GC) is increasingly defined by the complex interplay within the oral-gastric microbial axis. This conceptual shift extends beyond the classical Helicobacter pylori (H. pylori) model. Instead, it encompasses a broader polymicrobial network. Mechanisms underlying ectopic colonization of oral pathobionts are examined alongside their synergistic contributions to mucosal dysbiosis. Remodeling of the tumor microenvironment is discussed through the analysis of critical functional modules, including biofilm formation, metabolic reprogramming, and immune dysregulation. Carcinogenesis is reportedly promoted by specific genotoxic metabolites and perpetuation of chronic inflammation. Diagnostic capabilities are evaluated with a focus on noninvasive biomarkers, where integration of artificial intelligence for risk stratification is identified as a transformative tool for early detection. Furthermore, therapeutic perspectives are expanded by evidence linking microbial composition to the efficacy of immune checkpoint inhibitors and chemotherapy. Strategies for prevention and treatment are proposed based on restoration of microbial homeostasis. Collectively, a roadmap for translating microbiome research into personalized clinical practice for gastrointestinal malignancies is provided by this review.
Hepatocellular carcinoma accounts for 90% of primary liver malignancies and ranks as the fourth leading cause of global cancer mortality. DNA methylation drives HCC pathogenesis by orchestrating tumor suppressor silencing and oncogenic pathway activation, fundamentally governing tumor heterogeneity and therapeutic resistance. While alterations in white blood cell counts have emerged as independent prognostic indicators in HCC progression, their causal relationship with tumor epigenetics remains unclear. Given that HCC tumors actively secrete cytokines and remodel systemic immunity through epigenetic mechanisms, peripheral white blood cell dynamics serve as a compelling surrogate for studying tumor-driven immune dysregulation and identifying methylation-based therapeutic targets. We integrated DNA methylation profiles from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) with summary statistics from six genome-wide association studies of white blood cell counts. Using these data, we applied a two-sample Mendelian Randomization (MR) framework to systematically investigate the causal effects of HCC-related CpG sites on white blood cell counts. The robustness of our findings was established through stringent criteria, comprehensive sensitivity analyses, and Bayesian colocalization, followed by functional validation with TCGA data and a transcriptome-wide association study (TWAS). Our analysis identified 26 HCC-specific CpG sites with causal effects on white blood cell counts. A multi-step validation pipeline integrating Bayesian colocalization and tumor-specific expression analysis robustly confirmed three core mediator genes: BTN3A2, TRIM27, and S100A12. TWAS provided independent, gene-level validation, revealing BTN3A2 as a powerful regulator of lymphocyte and neutrophil counts, TRIM27 as a key immunometabolic checkpoint, and S100A12 as a modulator of innate immunity. This study establishes epigenome-immune crosstalk in HCC by identifying BTN3A2, S100A12 and TRIM27 as central methylation-immunoregulatory hubs. The discovered methylation-immune axes provide mechanistic insights for developing combination therapies targeting epigenetic checkpoints to reverse immunosuppressive microenvironments in advanced HCC.
Pancreatic cancer remains one of the most lethal malignancies, and its frequent spread to the peritoneum significantly compromises patient survival and quality of life. Peritoneal metastasis arises from a complex interaction between tumor intrinsic features and the unique anatomical and immune environment of the peritoneal cavity. This review systematically elucidates the stepwise process of peritoneal dissemination, including initial cell detachment, epithelial-to-mesenchymal transition, resistance to anoikis, immune evasion, adhesion to the mesothelium, and angiogenesis. We then highlight four interconnected regulatory hubs that drive these events: metabolic reprogramming that supports tumor survival and reinforces immune suppression; extracellular vesicles that enable intercellular communication and premetastatic niche formation; cancer stem cells that confer phenotypic flexibility and therapy resistance; and the dynamically remodeled immune microenvironment that facilitates tumor colonization. Finally, we critically assess emerging locoregional treatment strategies, namely normothermic, hyperthermic, and pressurized intraperitoneal chemotherapy, designed to overcome the peritoneal-plasma barrier and improve clinical outcomes. Furthermore, we evaluate the potential synergistic effects of integrating these strategies with immunotherapy. By synthesizing current knowledge of the molecular and cellular mechanisms underlying peritoneal metastasis in pancreatic cancer, this review offers a conceptual framework for developing precision-targeted interventions against this devastating condition.